AZN.L
$14364.00
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Intraday
Recent News
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kyntra Bio, Inc.'s filings with the SEC, including our most recent Form 10-K and Form 10-Q. Kyntra Bio, Inc. does not undertake any obligation to update publicly any forward-looking statements whether as a result of new information, future events, or otherwise.
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp
AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price target on AstraZeneca PLC (NASDAQ:AZN) to 16,000 GBp from 15,500 GBp on March 10, reiterating a Buy rating on the shares and telling investors that it is updating its model after the company’s fiscal 2025 […]
AstraZeneca’s Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer
The EU approval of Imfinzi for early-stage gastric and gastroesophageal cancers expands the label of one of the company’s top-selling oncology medicines.
Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?
MRK bets on new products and a growing pipeline as Keytruda nears 2028 LOE, with $70B potential commercial opportunities projected by mid-2030s.
£50bn construction giant abandons London stock market
Building materials giant CRH is to quit the London Stock Exchange (LSE) in a further blow to Britain’s standing as a global financial hub.